Verastem VSTM shares are trading higher after the company announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer.
Verastem's stock is trading up 25.08% to a price of $3.88. The stock's current volume for the day is 14.14 million, which is approximately 723.89% of its previous 30-day average volume of 1.95 million.
The 50-day moving average price of Verastem's stock was $2.73 when this article was published. The stock reached a high of $3.29 and a low of $1.08 in the past 52 weeks.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
